Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: Strategies and pitfalls

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 179-184

  Brandes, Alba A ^a   Franceschi, Enrico ^a   Tosoni, Alicia ^a   Esposti, Roberta Degli ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

HER2; Lapatinib; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENTIATION; DRUG WITHDRAWAL; HEART DISEASE; HUMAN; METASTASIS; OVERALL SURVIVAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM METASTASIS; QUINAZOLINES;

EID: 76749083897     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.156     Document Type: Review

References (34)

1. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77 (1998).
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005). •• Milestone paper on the use of trastuzumab in the adjuvant setting.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005). •• Milestone paper on the use of trastuzumab in the adjuvant setting.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). • Pivotal Phase III trial on the use of trastuzumab and chemotherapy in the metastatic setting.
6. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11, 318-324 (2006).
7. Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that over expresses HER-2. Oncologist 13, 1114-1119 (2008).
8. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
9. Baselga J, Carbonell X, Castaneda-Soto NJ et al. PhaseII study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162-2171 (2005).
10. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96, 739-749 (2004).
11. Marty M, Cognetti F, Maraninchi D et al. Randomized PhaseII trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265-4274 (2005).
12. Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23, 2502-2512 (2005).
13. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
14. Pusztai L, Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest. 24, 187-191 (2006).
15. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
16. Nahta R, Takahashi T, Ueno NT et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64, 3981-3986 (2004).
17. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8, 215 (2006).
18. Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
19. Lu CH, Wyszomierski SL, Tseng LM et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 13, 5883-5888 (2007).
20. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628-638 (2007).
21. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin. Breast Cancer 4, 120-125 (2003).
22. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer 5, 52-58 (2004).
23. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 22, 1063-1070 (2004).
24. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6, 63 (2006).
25. Fabi A, Metro G, Ferretti G et al. DoHER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 17, 499-505 (2008).
26. Cancello G, Montagna E, D'Agostino D et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 10, R60 (2008).
27. Montemurro F, Redana S, Nole F et al. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer 8, 209 (2008).
28. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J. Clin. Oncol. 27(12), 1999-2006 (2009). • Phase III trial, which was prematurely interrupted, on the use of trastuzumab and chemotherapy beyond trastuzumab progression in the metastatic setting.
29. Extra J-M, Antoine E-C, Vincent-Salomon A et al. Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res. Treat. 100(Suppl. 1), S102 (2006).
30. Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother. Pharmacol. 53, 186-190 (2004).
31. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006). •• Pivotal Phase III trial on the use of lapatinib and chemotherapy in the metastatic setting.
32. Blackwell KL, Burstein H, Pegram M et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 3004).
33. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993-1999 (2008).
34. O'Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26, 1015 (2008).